Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Livzon Pharmaceutical Group ( (HK:1513) ) just unveiled an update.
Livzon Pharmaceutical Group has approved and signed a series of 2026 framework agreements with its connected subsidiary Livzon MAB to govern continuing connected transactions for the year ending 31 December 2026. Under these agreements, the group will supply water, electricity, steam, natural gas and sewage treatment services, lease assets, purchase drugs from Livzon MAB, and provide labour services, with respective annual caps of RMB20 million, RMB35 million, RMB75 million and RMB80.5 million. As Livzon MAB is deemed a connected person through common shareholding by controlling shareholder Joincare, these arrangements fall under continuing connected transactions as defined by Hong Kong Listing Rules, triggering reporting and announcement obligations but remaining exempt from shareholder approval due to their size. The structured caps and formalized contracts underscore the company’s efforts to standardize intra-group dealings, support Livzon MAB’s operations and ensure regulatory compliance, while clarifying the financial scope of related-party transactions for investors and other stakeholders.
The most recent analyst rating on (HK:1513) stock is a Sell with a HK$37.23 price target. To see the full list of analyst forecasts on Livzon Pharmaceutical Group stock, see the HK:1513 Stock Forecast page.
More about Livzon Pharmaceutical Group
Livzon Pharmaceutical Group is a China-based pharmaceutical company listed in Hong Kong, operating in the healthcare and biopharmaceutical industry. Its business covers the production and sale of drugs and related services, and it maintains close operational ties with Livzon MAB, a connected subsidiary engaged in biopharmaceutical activities, reflecting a vertically integrated structure within its broader pharmaceutical operations.
Average Trading Volume: 735,449
Technical Sentiment Signal: Hold
Current Market Cap: HK$32.19B
Learn more about 1513 stock on TipRanks’ Stock Analysis page.